Market Updates Meningococcal-Vaccines Market Research Report 2022 | Page 2

septicemia, pneumonia, meningitis, and meningococcemia. It can be categorized based on their immunologic
reactivity. Presently, the global meningococcal vaccines are of four types which include bivalent (serogroup A and C),
tetravalent (serogroup A, C, Y, and W-135), polysaccharide based, and trivalent (serogroup A, C, and W-135).
There is, presently, only a single vaccine available for serogroup B in the U.S., even though it accounted for more than
one-third of the diseases cases in the country. The components and nature of the vaccines are heat-stable, purified,
lyophilized capsular polysaccharides derivative of the meningococcal of the corresponding serogroups. The major
factor driving the growth of global meningococcal vaccines market includes the growing occurrence of meningitis
across the globe. Growing awareness about the diseases and their vaccines is also driving the overall market. Other
factors responsible for the growth of the market include several public-private partnerships for carrying out research
& development activities, manufacturing quality vaccines at affordable prices, and the presence of vaccines in a
pipeline and their expected commercialization. Additionally, rising government interventions in refining healthcare
infrastructure, numerous awareness programs, and incorporation of security guidelines concerning meningococcal
vaccines are also projected to positively impact the global meningococcal vaccines market. The introduction of
advanced serotype B vaccines from large global drug makers including Pfizer and Novartis further boosts the demand.
Get a Sample Copy of This Report @
https://www.millioninsights.com/industry-reports/meningococcal-vaccines-market/request-sample
However, factors restraining the growth of the global meningococcal vaccines market include rising financial severity
in the European region, serotype mismatch and less than optimum coverage across countries. A delay in accessing the
disease epidemiology over regular intervals because of cost issues is expected to negatively impact the overall market
in the developing countries. The prime barrier of the market includes the maintenance of cold chain for the delivery
of vaccines leads to rising in the cost of vaccination. Other factors such as high cost of vital vaccines, including Bexsero
and the requirement for effective cold chain logistics to maintain efficacy, price wars for vaccines from equivalent drug
makers that could eradicate the customer base and safety of the vaccines may also hinder the growth of the global
meningococcal vaccines market.
North America emerged as the regional leader of the global meningococcal vaccines market on account of rising
government prevention & intervention programs, and research & development activities by numerous manufacturers.
The increased awareness about the health care facilities is responsible for the growth in the region. The majority of
the revenue was generated by the U.S. in North America. However, Asia-Pacific meningococcal vaccines market is
projected to have the highest growth rate in the market over the next eight years. This high growth rate can be
attributed to factors such as increased spending on health care and low manufacturing costs. China, India, and Japan
are estimate